Nabriva Therapeutics PLC (NBRV)
2.07
+0.04 +1.97%
NASDAQ
Feb 22, 20:00
Delayed 2m
USD
View All Key Stats
NBRV Key Stats
| Income Statement | |
| Revenue (TTM) | 9.981M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -2.30 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -106.22M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -11.46K% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | Upgrade |
| Price and Valuation | |
| Market Cap | 139.32M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 8.994 |
| PE Ratio (TTM) | -- |
| Price to Book Value | 1.445 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | Upgrade |
| Free Cash Flow (Quarterly) | -17.17M |
| Return on Equity (TTM) | Upgrade |
View All NBRV News
NBRV News
-
WireHeadlineTime (ET)
-
MT Newswires02/19 14:38
-
SA Breaking News02/19 08:18
-
Globe Newswire02/19 07:00
-
SA Breaking News01/28 07:51
-
PR Newswire01/17 10:00
-
Yahoo01/15 08:58
-
Globe Newswire01/15 07:00
-
MT Newswires01/14 14:36
-
SA Breaking News01/14 07:18
-
Globe Newswire01/14 07:00
View All Events
NBRV Events
| Date | Type | Description |
|---|---|---|
| 08/09/2019 | Earnings | Nabriva Therapeutics PLC Second Quarter Earnings Results in 2019 |
| 11/06/2018 | Earnings | Nabriva Therapeutics PLC Third Quarter Earnings in 2018 Release |
| 08/09/2018 | Earnings | Nabriva Therapeutics PLC Second Quarter Earnings Results in 2018 |
| 08/01/2018 | Misc | Nabriva Therapeutics PLC Annual General Meeting in 2018 |
NBRV Fundamentals
Income Statement View Statement
NBRV Ratings
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
Advertisement
NBRV One Page Reports
- One Page Report Download
NBRV Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 2.07 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Edit
Profile
- URL: http://www.nabriva.com
- Investor Relations URL: N/A
- HQ State/Province: N/A
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: N/A
- Next Earnings Release: Aug. 09, 2019
- Last Earnings Release: Nov. 06, 2018
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Nabriva Therapeutics AG is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.
NBRV Excel Add-In Codes
- Name: =YCI("NBRV","name")
- Description: =YCI("NBRV","description")
- Sector: =YCI("NBRV","sector")
- Industry: =YCI("NBRV","industry")
- Est. Current Fiscal Year End: =YCI("NBRV","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other NBRV Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- NBRV Tweets Stocktwits
Advertisement
